MedTrace Logo

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

NCT01467011 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2018-05-16

No results posted yet for this study

Summary

The purpose of this study is to gather information regarding the use of Myfortic, Prograf, and corticosteroids in new liver transplant recipients. These three medicines help to prevent the body from rejecting the transplanted liver. The information the investigators are obtaining is data relating to the process of Myfortic absorption by the body, its distribution in the body, the breakdown of Myfortic in the body, and its elimination from the body. This absorption, distribution, breakdown, and elimination is called pharmacokinetics.

Conditions

  • End Stage Liver Disease

Interventions

DRUG

Enteric-coated Mycophenolate Sodium

1440mg/day for 6 months posttransplant

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • R. Mark Ghobrial, MD

    lead OTHER

Principal Investigators

  • R M Ghobrial, MD, PhD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-12-31
Completion
2013-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467011 on ClinicalTrials.gov